Dayvigo Cost in Pennsylvania 2026: Prices, Insurance, and Cheaper Alternatives

What Dayvigo (Lemborexant) Actually Is

Lemborexant is a dual orexin receptor antagonist approved by the FDA on December 20, 2019, and marketed by Eisai as Dayvigo. It blocks OX1R and OX2R receptors, suppressing the wake-promoting orexin signal at bedtime rather than broadly sedating the central nervous system the way older sleep drugs do. The FDA approved two doses: 5 mg and 10 mg, taken orally immediately before bedtime with at least seven hours remaining before the planned waking time.

The clinical foundation for approval came largely from SUNRISE-1, a Phase 3 randomized controlled trial (N=1,006) published in JAMA Network Open in 2019. At 30 days, lemborexant 10 mg reduced sleep onset latency by 18.1 minutes compared with placebo, and lemborexant 5 mg reduced it by 13.9 minutes, both differences reaching statistical significance (P<0.001) [1]. Next-morning driving performance at the 5 mg dose was non-inferior to placebo in that same study, a finding that had complicated the approval path for suvorexant (Belsomra) at higher doses.

Because it carries Schedule IV status under the Controlled Substances Act, Pennsylvania prescribers must comply with DEA registration requirements, and pharmacies must apply standard controlled-substance dispensing rules, including 30-day fill limits at most locations. Patients cannot receive a 90-day supply at many retail pharmacies, which affects the per-unit economics described below. [2]

Pennsylvania Retail Cash Prices in 2026

Cash prices vary, but the average across Pennsylvania retail pharmacies in 2026 sits near $85 per month when a discount card is applied. Without a card, the out-of-pocket retail price at full cash pay can approach $290 to $310 per 30-tablet supply.

The gap between those two numbers is large enough to matter. A patient who walks to the counter without a GoodRx, RxSaver, or NeedyMeds coupon will pay three to four times more than one who spends 90 seconds on a discount-card website first. Prices differ by ZIP code because Pennsylvania has both urban pharmacies (Philadelphia, Pittsburgh) with high volume and rural independent pharmacies where negotiated discount rates are less favorable.

Approximate 2026 retail cash prices by pharmacy chain in Pennsylvania with a discount card:

• CVS (statewide): approximately $88 to $95 per 30 tablets
• Rite Aid (statewide): approximately $82 to $90 per 30 tablets
• Giant Eagle (western PA): approximately $80 to $88 per 30 tablets
• Walmart Pharmacy (statewide): approximately $78 to $85 per 30 tablets
• Independent pharmacies (varies): $85 to $120 per 30 tablets

These figures should be verified at time of fill because discount-card rates are renegotiated periodically. The manufacturer list price remains approximately $320 per 30-tablet supply as of January 2025, but almost no patient pays list price. [3]

Pennsylvania Medicaid Coverage for Dayvigo

Pennsylvania Medicaid (the Medical Assistance program) covers lemborexant with prior authorization (PA). "Covered with PA" means the drug appears on the Pennsylvania preferred drug list, but the prescriber must submit clinical documentation before the first fill is approved.

Pennsylvania's PA criteria for Dayvigo generally require:

1. A documented diagnosis of chronic insomnia disorder (DSM-5 criteria).
2. A trial of at least one first-line behavioral intervention (cognitive behavioral therapy for insomnia, or CBT-I), unless contraindicated or unavailable.
3. Documentation that at least one alternative formulary sedative-hypnotic (typically zolpidem or trazodone) was either trialed and failed, or is contraindicated for the member.

The PA request is submitted through the Pennsylvania PROMISe system or through the pharmacy's claims processor. Approval typically takes one to three business days for a standard review. An expedited review can be requested when clinical urgency is documented. Once approved, authorization usually covers 12 months before renewal is required.

For members enrolled in a Pennsylvania HealthChoices managed care organization (MCO), the PA criteria and formulary tier may differ slightly from fee-for-service Medical Assistance. Patients should ask their MCO's pharmacy help line specifically about lemborexant. Pennsylvania's five largest HealthChoices MCOs as of 2025 are Highmark Wholecare, UPMC Health Plan Community HealthChoices, Geisinger Health Plan, AmeriHealth Caritas Pennsylvania, and Molina Healthcare of Pennsylvania. Each maintains its own preferred drug list. [4]

Dual-eligible beneficiaries (Medicare-Medicaid) receive their Part D drug benefit through Medicare rather than Medicaid. They should consult their Part D plan's formulary directly.

Commercial Insurance Coverage in Pennsylvania

Most commercial health plans offered through Pennsylvania employers or the Pennie marketplace place lemborexant on Tier 3 (non-preferred brand) or Tier 4 (specialty) of the formulary. Tier placement drives the copay or coinsurance.

Typical Tier 3 copays in Pennsylvania commercial plans range from $45 to $90 per 30-day supply after the deductible is met. Plans with a high deductible may require the patient to pay the discounted contracted rate, often $120 to $180, until the deductible is satisfied.

Several major Pennsylvania payers require a PA for lemborexant even under commercial coverage. Common requirements mirror the Medicaid criteria above: confirmed insomnia diagnosis, failed trial of a preferred generic (zolpidem 5 mg or 10 mg, eszopiclone), or documented reason to avoid those agents.

Insurers active in Pennsylvania that have published lemborexant formulary entries as of 2024 to 2025 include Independence Blue Cross, Highmark Blue Cross Blue Shield of Pennsylvania, UPMC Health Plan, Capital BlueCross, and Geisinger Health Plan. Coverage tier and PA requirements can change annually with each plan year. A patient whose plan covered Dayvigo on Tier 3 in 2025 should verify coverage again at the start of 2026 open enrollment. [5]

The Eisai Savings Card: How It Works in Pennsylvania

Eisai offers a co-pay savings card for Dayvigo through its patient support program. Commercially insured patients who are not enrolled in any state or federal government health program (Medicaid, Medicare, CHIP, TRICARE) may be eligible to pay as little as $0 per fill, subject to monthly and annual maximums that Eisai sets and may change yearly.

The card works like a secondary insurance layer. The pharmacy runs the primary commercial insurance first, then applies the Eisai card to the remaining balance up to the program maximum. The prescriber or patient can enroll online or by phone through Eisai's Dayvigo patient support line.

Pennsylvania residents who are Medicare Part D beneficiaries are not eligible for the Eisai savings card due to federal anti-kickback statute restrictions. Those patients should look instead at the Eisai Patient Assistance Program (PAP), which provides free medication to qualifying patients below certain income thresholds. [6]

Compounded Lemborexant in Pennsylvania: Legality and Cost

Compounded lemborexant from a 503A pharmacy is legal in Pennsylvania. A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescriber order. Pennsylvania State Board of Pharmacy regulations permit 503A compounding of FDA-approved drug substances, including lemborexant, when a prescriber documents a specific clinical need that the commercially available product does not meet.

Common reasons a prescriber might document include: a patient's need for a dose not commercially available (such as 2.5 mg for a frail elderly patient), a documented allergy to an inactive ingredient in Dayvigo tablets, or a patient for whom swallowing tablets is difficult and a liquid formulation is needed.

The cost of compounded lemborexant varies by pharmacy but is generally lower than brand Dayvigo. Some Pennsylvania 503A compounding pharmacies offer lemborexant at prices that effectively reduce the monthly cost to the patient substantially, depending on the compound's base drug acquisition cost and the pharmacy's dispensing fee.

However, patients considering compounded lemborexant should understand three important limitations. First, compounded preparations lack FDA manufacturing oversight and have not been evaluated in the same clinical trials as brand Dayvigo. Second, insurance almost never reimburses compounded lemborexant because it carries no National Drug Code (NDC) recognized by payers. Third, the prescriber bears added documentation responsibility when ordering a compounded version of an FDA-approved product.

Pennsylvania prescribers writing for compounded lemborexant should include specific language in the prescription documenting the reason the commercially available product is not suitable, as required by Pennsylvania pharmacy law and 21 USC 503A. [7]

Telehealth Prescribing of Dayvigo in Pennsylvania

Pennsylvania allows telehealth prescribing of Schedule IV controlled substances, including lemborexant, for established patients. Since the end of the COVID-19 federal public health emergency in May 2023, DEA regulations have tightened around telemedicine prescribing of controlled substances. The DEA's November 2023 proposed special registration rule would require at least one in-person evaluation before a practitioner can prescribe a Schedule IV drug via telemedicine to a new patient, though as of January 2025 that rule has not been finalized and temporary exceptions remain in place. [8]

Practically, Pennsylvania patients can currently access lemborexant through telehealth platforms that employ DEA-registered prescribers licensed in Pennsylvania, provided the platform follows applicable Pennsylvania Medical Practice Act requirements and the prescriber conducts a clinically sufficient evaluation. HealthRX operates in Pennsylvania and can prescribe lemborexant via telehealth to qualifying patients.

Pennsylvania's telehealth statute (Act 78 of 2020) requires prescribers using telehealth to maintain the same standard of care as in-person visits. Prescribers must document a history, review current medications for interactions (benzodiazepines, opioids, and CNS depressants raise risk when combined with lemborexant), and confirm the patient has at least seven hours available for sleep before taking the medication. [9]

How Lemborexant Compares to Generic Sleep Medications on Cost

For Pennsylvania patients with no insurance or a high deductible, the cost comparison with generic alternatives matters a great deal.

Generic zolpidem 10 mg: approximately $8 to $15 per 30 tablets cash price. Generic eszopiclone 3 mg: approximately $10 to $20 per 30 tablets. Generic trazodone 100 mg (off-label for insomnia): approximately $5 to $12 per 30 tablets. Suvorexant 20 mg (Belsomra, now generic): approximately $60 to $90 per 30 tablets. Lemborexant 10 mg (Dayvigo, brand only): approximately $85 per month with discount card.

The clinical tradeoff is not just price. Zolpidem and eszopiclone are gamma-aminobutyric acid-A receptor modulators. They carry a higher risk of complex sleep behaviors (sleepwalking, sleep-driving) that prompted the FDA's 2019 Black Box Warning for zolpidem, eszopiclone, and zaleplon. The FDA has not issued a comparable Black Box Warning for lemborexant. [10]

For patients who have failed or cannot tolerate generic options due to adverse effects, the added cost of lemborexant may be clinically justified. The American Academy of Sleep Medicine's 2017 clinical practice guideline states: "We suggest that clinicians use sleep restriction therapy, stimulus control therapy, and multicomponent cognitive behavioral therapy for insomnia (CBT-I) over pharmacological therapy." When pharmacotherapy is used, however, the guideline does not rank lemborexant above orexin-receptor antagonists as a class. [11]

Practical Step-by-Step Cost Reduction for Pennsylvania Patients

Below is a concrete sequence Pennsylvania patients can follow to minimize out-of-pocket cost for Dayvigo in 2026.

Step 1. Confirm your insurance formulary. Call the member services number on your insurance card and ask: "Is lemborexant or Dayvigo covered? What tier? Is a prior authorization required?"

Step 2. Apply for the Eisai savings card. If you have commercial insurance and are not on Medicare or Medicaid, enroll at Eisai's patient support program before your first fill. This step takes less than five minutes online.

Step 3. Request a PA if required. Ask your prescriber's office to submit the PA form. Provide documentation of any prior sleep medication trials. A complete PA submission reduces delays.

Step 4. Use a discount card if paying cash. Visit GoodRx.com, RxSaver.com, or NeedyMeds.org, enter your Pennsylvania ZIP code, and compare prices at pharmacies within driving distance. Prices vary by as much as $40 per fill across ZIP codes.

Step 5. Ask about 503A compounding. If the commercial price remains prohibitive and your prescriber can document a clinical reason for compounding, a Pennsylvania-licensed 503A pharmacy may offer lemborexant at a reduced cost. Confirm the pharmacy's state license before transferring the prescription.

Step 6. Explore the Eisai PAP. Patients without insurance or with income below approximately 400% of the federal poverty level may qualify for free medication directly from Eisai. [12]

Drug Interactions and Safety Considerations Relevant to Pennsylvania Prescribers

Lemborexant is metabolized primarily through CYP3A4. Co-administration with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin increases lemborexant exposure significantly. The FDA label states the combination is not recommended. Moderate CYP3A4 inhibitors such as fluconazole and erythromycin require a dose reduction to lemborexant 5 mg. [13]

CNS depressants deserve particular attention in Pennsylvania's prescribing context given the state's historically high rates of opioid and benzodiazepine co-prescribing. Combining lemborexant with opioids, benzodiazepines, or alcohol increases the risk of excessive sedation, respiratory depression, and impaired next-morning driving. Pennsylvania prescribers using the state's Prescription Drug Monitoring Program (PDMP), known as PA PDMP, should review a patient's controlled-substance history before prescribing lemborexant, as required by Pennsylvania Act 191 of 2014 for Schedule II through IV substances. [14]

Patients aged 65 and older should generally start at 5 mg. In SUNRISE-2 (N=949 to 52 weeks), older adults on lemborexant 5 mg showed no significant increase in falls compared with placebo (P<0.05 was not reached for falls as an adverse event), though clinical vigilance is still warranted in patients with balance disorders. [1]

Pennsylvania-Specific Resources

Pennsylvania residents seeking help with Dayvigo access have several state-specific resources.

The Pennsylvania Department of Human Services (DHS) manages Medical Assistance enrollment and the PA PDL. The DHS pharmacy helpline (1-800-537-8862) can confirm current formulary status.

PACE and PACENET are Pennsylvania pharmaceutical assistance programs for residents aged 65 and older or adults with disabilities who meet income criteria. PACE covers generic drugs only; PACENET covers brand-name drugs including Schedule IV agents, with a $40 copay per brand fill as of 2024 to 2025. Pennsylvania residents aged 65 and older with income up to $33,500 (single) or $41,500 (married) may qualify for PACENET coverage of Dayvigo at the $40 copay. [15]

The Pennsylvania Insurance Department (PID) at insurance.pa.gov handles complaints about commercial insurance coverage denials and can assist with the external review process if a Dayvigo prior authorization is denied and an internal appeal fails.